

Ref no: 147250319
From: Commercial
Date: 25/03/19
Subject: Vyxeos to treat patients with Acute Myeloid Leukemia

REQUEST & RESPONSE

Please find below a request for information regarding the use of Vyxeos to treat patients with Acute Myeloid Leukemia (AML) at your Trust. Four Communications is carrying out this request on behalf of Jazz Pharmaceuticals.

I would be grateful if you could provide the answers to these questions within the timeframe specified by the Freedom of Information Act 2000. If you have any concerns in relation to responding to these questions within this timeframe, please do not hesitate to get in touch with me at matthew.humphreys@fourcommunications.com or 020 3697 4353.

1. Is Vyxeos an approved therapy on the trust formulary for patients with Acute Myeloid Leukemia (AML)?

Yes, it is NICE approved, so it is available for us to use.

2. What e-prescribing system does the Trust use?

The Trust uses Chemocare.

3. Is Vyxeos now available to be prescribed through the Trust's e-prescribing system?

This drug will be set up to be used on Chemocare as soon as possible.